XENE
Xenon Pharmaceuticals Inc
36.60$
-6.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -26.8% | +5.5% | -31.7% | +165.4% | +20.6% | +28.1% | +202.4% | +31.8% | +27.9% | -17.3% | +23.0% | |
| – | -28.3% | +7.9% | -31.8% | +170.9% | +19.3% | +25.5% | +207.5% | +7.4% | +7.4% | -1.5% | -11.7% | |
| – | -18.6% | -70.9% | +19.8% | +230.7% | -63.5% | +81.8% | +290.3% | -67.4% | +159.7% | -4.0% | +39.6% | |
| – | -30.2% | +9.4% | -31.9% | +173.2% | +18.5% | +25.2% | +211.7% | +7.3% | +7.8% | -1.8% | -12.4% | |
| – | +46.5% | -36.5% | +119.0% | -41.6% | +217.6% | +124.1% | +51.8% | -64.3% | -11.4% | +68.1% | -6.7% | |
| – | -31,500,100.0% | – | +0.0% | – | – | – | – | – | – | – | – | |
| – | -19.7% | -29.4% | -23.8% | -7.4% | +67.5% | +114.1% | +25.7% | +45.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -80.1% | +23.0% | +184.1% | +87.8% | +191.2% | -68.0% | +23.2% | +48.6% | +12.9% | +17.2% | +824.9% | |
| – | -80.5% | +26.4% | +16.1% | +0.9% | +953.1% | -65.9% | -3.1% | +58.5% | +20.1% | +30.5% | +17.4% | |
| – | – | – | – | +2,044.9% | -67.9% | -94.5% | +128.3% | -19.3% | +166.2% | +5.4% | +11.9% | |
| – | +96.7% | +34.5% | -14.4% | -46.9% | +271.9% | +23.0% | +25.7% | +122.0% | +1.3% | -41.0% | -23.4% | |
| – | – | – | – | +146.0% | -27.5% | – | – | – | – | – | – | |
| – | -16.1% | +4.7% | -43.8% | +187.5% | -11.0% | +86.3% | +221.0% | +31.2% | +28.6% | -18.6% | -22.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.8% | +8.5% | +16.2% | +7.9% | +33.5% | +33.2% | +26.3% | +38.8% | +10.5% | +16.5% | +1.7% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.